# Kura Oncology Inc. (KURA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.25, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Kura Oncology Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 15.3×**. Each dollar of revenue is priced at 15.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 24.4×**. The shares trade at 24.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -10.0%** (5-yr avg -5.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -411.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -412.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -160.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -723.2%**. Return on all capital, debt included, is -723.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -40.2%**. Each dollar of assets produces -40.2% of profit.

## Growth
- **Revenue growth (1 yr): 25.2%**. Revenue grew 25.2% over the last year.
- **EPS growth (1 yr): -57.4%**. Earnings per share fell 57.4%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.06**. Debt is 0.06 times equity: a conservative balance sheet.
- **Altman Z-score: 0.32**. A Z-score of 0.32 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Kura Oncology Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Kura Oncology Inc.; the consensus is strong_buy, with an average price target of $32.00 (+142% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 63.0%** (YTD 27.5%, 3-mo 51.6%). The shares are up 63.0% over twelve months including dividends.
- **From 52-week high: -4.7%** (80.1% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 66**. An RSI of 66 is neutral.
- **Beta (1 yr): 1.43** (volatility 60%). Beta of 1.43 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=KURA · Page: https://foliofundamentals.com/stocks/kura

Not investment advice.